A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)
The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or SGLT-2 (sodium-glucose cotransporter-2) inhibitor.
Key RequirementsClinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.
Have Type 2 Diabetes
Be taking a consistent dose of diabetes drug by injection for at least 3 months
May be taking up to 2 diabetes drugs by mouth for at least 3 months
Have a high blood sugar
Participants Must Not:
Have Type 1 diabetes
Have history of an inflamed pancreas (pancreatitis)
Have history of an inflamed liver (hepatitis)
Have congestive heart failure
Lilly Trial Alerts
Take the Next Step
- Select which clinical trial site works best for you.
- Share your details and questionnaire directly with site(s) that allow this.
- Get contact details for the site(s) of your choice.
Completing the Trial Match questionnaire doesn’t mean that you will be enrolled in a study. There may be more eligibility criteria for the study which are assessed by the Lilly clinical team.
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo